Press Releases

 
Press Releases
  Date Title and Summary View
Jan 27, 2016
PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI), today reported that Mohan Kabadi, PhD, Assembly's Vice President of Pharmaceutical Development, presented Gemicel...
Jan 11, 2016
INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level hires across the organization. The added team members include Richard...
Dec 21, 2015
INDIANAPOLIS, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced the appointment of Alan J. Lewis, PhD, to the company's board of directors. Dr. Lewis has had ...
Dec 16, 2015
INDIANAPOLIS, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the company will participate in the Jefferies Microbiome Summit being held today in Boston, MA....
Dec 9, 2015
—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver Selected Bacteria Strains to the GI Tract that Recapitulate the Effects of FMT as Treatment for CDI— NEW YORK, Dec. 09, 2015 ...
Oct 6, 2015
—Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— —Assembly Also Reporting New Peer-Reviewed Publication Highlighting Key Role of HBV Core Protein—            NEW YORK and BAD NAUHEIM, Germany, Oct....
May 19, 2015
NEW YORK and PARIS, May 19, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that Adam Zlotnick, PhD, Assembly's Chief Scientific Advisor and Chair of its HBV & Virology Science Advisory Board, discussed the science underlying the company's Core Protein Allosteric Modifiers (CpAMs) at the Second ANRS HBV Cure Worksh...
Mar 19, 2015
NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly") announced today the pricing of an underwritten public offering of $75 million, or 5,555,555 shares of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a pub...
Mar 18, 2015
NEW YORK, March 18, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly") announced today that it is commencing an underwritten public offering of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission. All of the shares in the offering ar...
Feb 20, 2015
NEW YORK, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in the 2015 RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York City. Assembly's Chief Executive Officer Derek Small and Chief Medical Officer Uri Lopatin will present on February 25, 2015 at 4...
Page:
1
NextLast
= add release to Briefcase

Investor Data

© 2016 Assembly Biosciences

Back to top